An international meta-analysis led by CNIC and published in The New England Journal of Medicine confirms that beta-blockers provide no clinical benefit in patients who have suffered a heart attack and maintain normal cardiac function (LVEF ≥ 50%).
The study analyzed individual data from 17,801 patients included in five clinical trials (REBOOT, REDUCE-AMI, BETAMI, DANBLOCK, and CAPITAL-RCT) and concluded that these treatments do not reduce mortality, recurrent heart attacks, or heart failure -regardless of age, sex, or beta-blocker type.
In fact, data from the REBOOT trial suggest they may even be harmful in women. After nearly four years of follow-up, the risk of major cardiovascular events was similar in both groups (with and without beta-blockers).
This finding, presented at the American Heart Association Congress, marks a significant change in clinical practice for millions of patients worldwide.
